Halozyme and Oruka sign agreement for Hypercon technology
Pharmaceutical Technology
Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.
pharminent
May 7, 2026 (Last updated: May 7, 2026)
Pharmaceutical Technology
Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology.